710 related articles for article (PubMed ID: 10493212)
1. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
2. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
Okugawa Y; Wada H; Noda T; Sakakura M; Nakasaki T; Watanabe R; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Deguchi K; Nobori T; Shiku H
Am J Hematol; 2000 Nov; 65(3):210-4. PubMed ID: 11074537
[TBL] [Abstract][Full Text] [Related]
3. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor pathway inhibitor; its structure, function and clinical significance.
Kato H
Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
[TBL] [Abstract][Full Text] [Related]
5. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation.
Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Deguchi H; Mori Y; Kaneko T; Deguchi K; Fujii J; Shiku H
Am J Hematol; 1996 Apr; 51(4):255-60. PubMed ID: 8602623
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
Saito M; Morishita E; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Matsuda T
Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
[TBL] [Abstract][Full Text] [Related]
8. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
[TBL] [Abstract][Full Text] [Related]
9. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.
Bregengård C; Nordfang O; Wildgoose P; Svendsen O; Hedner U; Diness V
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):699-706. PubMed ID: 8292719
[TBL] [Abstract][Full Text] [Related]
10. [Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation].
Fukuda C; Iijima K; Nakamura K
Rinsho Byori; 1996 Aug; 44(8):750-6. PubMed ID: 8816061
[TBL] [Abstract][Full Text] [Related]
11. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
[TBL] [Abstract][Full Text] [Related]
13. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Seo JW; Kim HK; Kim JE; Park S; Cho HI
Thromb Res; 2009 Feb; 123(4):565-72. PubMed ID: 18479738
[TBL] [Abstract][Full Text] [Related]
15. Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation.
Matsuo T; Matsuo M; Sugimoto T; Wanaka K
Pathophysiol Haemost Thromb; 2007; 36(6):305-10. PubMed ID: 20224256
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group.
Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Mori Y; Deguchi K; Shiku H
Pol J Pharmacol; 1996; 48(2):225-8. PubMed ID: 9112656
[TBL] [Abstract][Full Text] [Related]
17. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
18. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.
Okajima K; Uchiba M; Murakami K; Okabe H; Takatsuki K
Am J Hematol; 1996 Mar; 51(3):186-91. PubMed ID: 8619398
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
20. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
